The ALLIANCE study is a randomized control trial comparing tenofovir alafenamide (TAF) vs tenofovir disoproxil fumarate (TDF) in HIV infection coinfected with hepatitis B in adults initiating first-line antiretroviral treatment. Patients were randomized to get either bictegravir/FTC/TAF vs dolutegravir plus FTC and TDF. Dr Anchalee Avihingsanon (Thai Red Cross AIDS Research Centre, Bangkok, Thailand) joins touchINFECTIOUS DISEASES to discuss the aims, design, inclusion criteria and the findings of the ALLIANCE trial.
The presentation entitled ‘Week 48 results of a Phase 3 randomized controlled trial of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) vs dolutegravir + emtricitabine/tenofovir Disoproxil Fumarate (DTG+F/TDF) as initial treatment in HIV/HBV-coinfected adults (ALLIANCE)’ was presented at the International AIDS Society (IAS) 29 July – 2 August, 2022.
- What were the aims, design and inclusion criteria of the ALLIANCE trial?
- What were the outcome measures of the study and how well were they achieved?
- What are the clinical implications of these findings?
Disclosures: Anchalee Avihingsanon has nothing to disclose in relation to this video.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Shanice Allen.
Share this Video
Related Videos In HIV
Moti Ramgopal, IDWeek 2022: Unmet needs and challenges around maintenance of HIV-1 virologic suppression
In this touchINFECTIOUS DISEASES interview, we met with Dr Moti Ramgopal (Midway Research Center, FL, USA) to discuss the unmet needs and challenges around maintenance of HIV-1 virologic suppression. Dr Ramgopal discusses challenges around stigma, social issues, tolerability, injection site reactions, and patient satisfaction with their current treatment regimen. Access an interview with Dr Moti […]
Moti Ramgopal, IDWeek 2022: Phase 3/3b FLAIR and ATLAS-2M pooled analysis – Efficacy and safety outcomes through week 96 by race
Long-acting cabotegravir + rilpivirine administered monthly or every 2 months is the first and only complete long-acting regimen recommended by treatment guidelines for the maintenance of HIV-1 virologic suppression. In this touchINFECTIOUS DISEASES interview, we met with Prof. Moti Ramgopal (Midway Research Center, FL, USA) to discuss a post hoc analysis of pooled outcomes for […]
Marina Klein, AIDS2022: Global health burden and the elimination of HIV, hepatitis B, and hepatitis C
There are number of challenges in the elimination of the three blood-borne viruses — HIV, hepatitis B (HBV), and hepatitis C (HCV). Treatment advances have been made with the introduction of highly effective antiviral agents into clinical practice, and prevention strategies. However, for worldwide elimination of these viruses, effective vaccines are required. Dr Marina Klein […]
Journal articles and more to your inbox
Get the latest clinical insights from touchINFECTIOUS DISEASESSign me up!